These are two incurable diseases whose progression we can only try to slow down.
However, 100% of patients followed for age-related macular degeneration (AMD) and diabetic retinopathy (1 million patients in France) are not compliant.
It is in particular to fight against this abandonment of follow-up
that the Swiss laboratory Novartis offers patients, via
their ophthalmologist, the free use of a serious game called
OdySight
published by the French Tilak Healthcare.
Its role: to help
monitor the evolution of the disease in their patients.
Read also
Pharmacy: Novartis plans to sell its generics
Appearing in the form of a puzzle, the representation of which is constantly changing, this game available on tablet and mobile is in fact promoted free of charge by Novartis, which pays an annual usage fee to the French publisher.
It has just announced the raising of 7 million euros in new money from specialized funds Elaia, Swen Capital Partners, Matmut Innovation and iBionext Growth Fund, the co-founder.
This article is for subscribers only.
You have 71% left to discover.
To cultivate one's freedom is to cultivate one's curiosity.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in